ZTS Quote, Financials, Valuation and Earnings

Biomarin Pharmaceutical has a net margin of 28.56% compared to Zoetis's net margin of 14.23%. Zoetis's return on equity of 48% beat Biomarin Pharmaceutical's return on equity of 6.29%.

Zoetis has a consensus price target of $211.25, signalling upside risk potential of 28.4%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $98.04 which suggests that it could grow by 46.18%. Given that Biomarin Pharmaceutical has higher upside potential than Zoetis, analysts believe Biomarin Pharmaceutical is more attractive than Zoetis.

Zoetis has a beta of 0.891, which suggesting that the stock is 10.852% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.289, suggesting its less volatile than the S&P 500 by 71.112%.

Zoetis has a quarterly dividend of $0.43 per share corresponding to a yield of 1.04%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zoetis pays 29.52% of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.4B, which are larger than Biomarin Pharmaceutical quarterly revenues of $745.7M. Zoetis's net income of $682M is higher than Biomarin Pharmaceutical's net income of $106.1M. Notably, Zoetis's price-to-earnings ratio is 31.18x while Biomarin Pharmaceutical's PE ratio is 40.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 8.29x versus 4.78x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Corcept Therapeutics has a net margin of 28.56% compared to Zoetis's net margin of 25.86%. Zoetis's return on equity of 48% beat Corcept Therapeutics's return on equity of 25.77%.

Zoetis has a consensus price target of $211.25, signalling upside risk potential of 28.4%. On the other hand Corcept Therapeutics has an analysts' consensus of -- which suggests that it could grow by 44.99%. Given that Corcept Therapeutics has higher upside potential than Zoetis, analysts believe Corcept Therapeutics is more attractive than Zoetis.

Zoetis has a beta of 0.891, which suggesting that the stock is 10.852% less volatile than S&P 500. In comparison Corcept Therapeutics has a beta of 0.555, suggesting its less volatile than the S&P 500 by 44.46%.

Zoetis has a quarterly dividend of $0.43 per share corresponding to a yield of 1.04%. Corcept Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zoetis pays 29.52% of its earnings as a dividend. Corcept Therapeutics pays out -- of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.4B, which are larger than Corcept Therapeutics quarterly revenues of $182.5M. Zoetis's net income of $682M is higher than Corcept Therapeutics's net income of $47.2M. Notably, Zoetis's price-to-earnings ratio is 31.18x while Corcept Therapeutics's PE ratio is 41.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 8.29x versus 9.16x for Corcept Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics has a net margin of 28.56% compared to Zoetis's net margin of --. Zoetis's return on equity of 48% beat Plus Therapeutics's return on equity of --.

Zoetis has a consensus price target of $211.25, signalling upside risk potential of 28.4%. On the other hand Plus Therapeutics has an analysts' consensus of $15.75 which suggests that it could grow by 1150%. Given that Plus Therapeutics has higher upside potential than Zoetis, analysts believe Plus Therapeutics is more attractive than Zoetis.

Zoetis has a beta of 0.891, which suggesting that the stock is 10.852% less volatile than S&P 500. In comparison Plus Therapeutics has a beta of 0.696, suggesting its less volatile than the S&P 500 by 30.45%.

Zoetis has a quarterly dividend of $0.43 per share corresponding to a yield of 1.04%. Plus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zoetis pays 29.52% of its earnings as a dividend. Plus Therapeutics pays out -- of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.4B, which are larger than Plus Therapeutics quarterly revenues of --. Zoetis's net income of $682M is higher than Plus Therapeutics's net income of -$2.9M. Notably, Zoetis's price-to-earnings ratio is 31.18x while Plus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 8.29x versus 1.38x for Plus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 28.56% compared to Zoetis's net margin of 37.71%. Zoetis's return on equity of 48% beat Vertex Pharmaceuticals's return on equity of -2.89%.

Zoetis has a consensus price target of $211.25, signalling upside risk potential of 28.4%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $493.61 which suggests that it could grow by 22.64%. Given that Zoetis has higher upside potential than Vertex Pharmaceuticals, analysts believe Zoetis is more attractive than Vertex Pharmaceuticals.

Zoetis has a beta of 0.891, which suggesting that the stock is 10.852% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.399, suggesting its less volatile than the S&P 500 by 60.102%.

Zoetis has a quarterly dividend of $0.43 per share corresponding to a yield of 1.04%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zoetis pays 29.52% of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.4B, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Zoetis's net income of $682M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, Zoetis's price-to-earnings ratio is 31.18x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 8.29x versus 9.86x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.